Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. (KRTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
KRTX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsKaruna Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 93.85% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.00B | -$0.01B | -93.85% |
| 2022-12-31 | $0.01B | -$0.03B | -71.22% |
| 2021-12-31 | $0.04B | +$0.04B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare KRTX revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Karuna Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Karuna Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Karuna Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
KRTX revenue · 4 questionsKRTX's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 93.85% year-over-year from $0.00B in FY2023.
▸ Source: FMP · Karuna Therapeutics, Inc. SEC filings · GAAP · Karuna Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026